APM - Aptorum Group Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.6000
-0.2100 (-5.51%)
At close: 4:00PM EDT

3.6000 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.8100
Open3.9000
Bid3.6100 x 1200
Ask4.1000 x 800
Day's Range3.6000 - 3.9800
52 Week Range1.6600 - 23.7500
Volume139,442
Avg. Volume64,941
Market Cap109.391M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman
    Business Wire

    Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman

    Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the appointment of Dr. Kira Sheinerman as the senior strategic consultant based in New York effective immediately.

  • Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report
    Business Wire

    Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report

    Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced an interview with its President, Darren Lui, will air on The RedChip Money Report television program. The interview will air Sunday, May 31, at 3 p.m. local time on Bloomberg International, available in 100+ million homes across Europe.

  • Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update
    Business Wire

    Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update

    Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced financial results for the fiscal year ended December 31, 2019, and provided a business update.

  • Aptorum Group Limited to Present at the Infectious Disease Virtual Conference
    Business Wire

    Aptorum Group Limited to Present at the Infectious Disease Virtual Conference

    Aptorum Group Limited (Nasdaq:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, including orphan diseases, infectious diseases and metabolic diseases, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020, 10:00 a.m. ET. Aptorum Group’s President and Executive Director Mr. Darren Lui will join a panel, which entitled "Non-antibiotic Anti-infectives." This panel is scheduled for 10:30 a.m. ET to 12:00 p.m. ET. To RSVP for the virtual conference, please click through: https://m-vest.com/insights/blog/Infectious-Disease-Virtual-Conference-2020

  • ACCESSWIRE

    Aptorum Group Limited to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020

    NEW YORK, NY / ACCESSWIRE / April 15, 2020 / Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global ...

  • Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
    Business Wire

    Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress

    Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provides an update on the Company’s operations in light of the recent declaration of the coronavirus outbreak as a pandemic declared by the World Health Organisation on March 11, 2020.

  • Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference
    Business Wire

    Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference

    Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Ian Huen, Chief Executive Officer and Executive Director, and Darren Lui, President and Executive Director, will present at the Solebury Trout Virtual Investor Conference on Thursday, April 2, at 12:00 pm ET. The conference will webcast at the Solebury Trout website (https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36519/indexl.html). The presentation length would be 25 minutes.

  • Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform
    Business Wire

    Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform

    Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong’s Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates.

  • ACCESSWIRE

    Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

    NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March ...